{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:02:07Z","timestamp":1794128527525,"version":"4.8.0"},"reference-count":220,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81900563"],"award-info":[{"award-number":["81900563"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["81802278"],"award-info":[{"award-number":["81802278"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"zhejiang key research and development program","award":["2020C03125"],"award-info":[{"award-number":["2020C03125"]}]},{"name":"zhejiang key research and development program","award":["2020C04016"],"award-info":[{"award-number":["2020C04016"]}]},{"DOI":"10.13039\/501100012165","name":"key technologies research and development program","doi-asserted-by":"publisher","award":["2017YFA0105701"],"award-info":[{"award-number":["2017YFA0105701"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00018-021-04096-y","type":"journal-article","created":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T18:03:44Z","timestamp":1645380224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Mesenchymal stem cell-based treatments for COVID-19: status and future perspectives for clinical applications"],"prefix":"10.1007","volume":"79","author":[{"given":"Lijun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhin Shaheed","family":"Kalyani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangxin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9193-3900","authenticated-orcid":false,"given":"Charlie","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,20]]},"reference":[{"issue":"10223","key":"4096_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395(10223):497\u2013506","journal-title":"Lancet (London, England)"},{"issue":"18","key":"4096_CR2","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708\u20131720","journal-title":"N Engl J Med"},{"issue":"3","key":"4096_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","volume":"19","author":"B Hu","year":"2021","unstructured":"Hu B, Guo H, Zhou P, Shi ZL (2021) Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19(3):141\u2013154","journal-title":"Nat Rev Microbiol"},{"issue":"7","key":"4096_CR4","doi-asserted-by":"publisher","first-page":"108737","DOI":"10.1016\/j.celrep.2021.108737","volume":"34","author":"TA Bates","year":"2021","unstructured":"Bates TA, Weinstein JB, Farley S, Leier HC, Messer WB, Tafesse FG (2021) Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2. Cell Rep 34(7):108737","journal-title":"Cell Rep"},{"issue":"10268","key":"4096_CR5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(20)32228-5","volume":"397","author":"A Lal","year":"2021","unstructured":"Lal A, Erondu NA, Heymann DL, Gitahi G, Yates R (2021) Fragmented health systems in COVID-19: rectifying the misalignment between global health security and universal health coverage. Lancet (London, England) 397(10268):61\u201367","journal-title":"Lancet (London, England)"},{"issue":"5","key":"4096_CR6","doi-asserted-by":"publisher","first-page":"e1008536","DOI":"10.1371\/journal.ppat.1008536","volume":"16","author":"D Tang","year":"2020","unstructured":"Tang D, Comish P, Kang R (2020) The hallmarks of COVID-19 disease. PLoS Pathog 16(5):e1008536","journal-title":"PLoS Pathog"},{"issue":"1","key":"4096_CR7","first-page":"157","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta D, Vanelli M (2020) WHO declares COVID-19 a pandemic. Acta Biomed 91(1):157\u2013160","journal-title":"Acta Biomed"},{"issue":"7809","key":"4096_CR8","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R Wolfel","year":"2020","unstructured":"Wolfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Muller MA, Niemeyer D, Jones TC, Vollmar P, Rothe C et al (2020) Virological assessment of hospitalized patients with COVID-2019. Nature 581(7809):465\u2013469","journal-title":"Nature"},{"key":"4096_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3389\/fimmu.2020.01091","volume":"11","author":"G Moll","year":"2020","unstructured":"Moll G, Drzeniek N, Kamhieh-Milz J, Geissler S, Volk HD, Reinke P (2020) MSC Therapies for COVID-19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy. Front Immunol 11:1091","journal-title":"Front Immunol"},{"issue":"11","key":"4096_CR10","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/cid\/ciaa1467","volume":"72","author":"H Kanamori","year":"2021","unstructured":"Kanamori H, Weber DJ, Rutala WA (2021) Role of the healthcare surface environment in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and potential control measures. Clin Infect Dis 72(11):2052\u20132061","journal-title":"Clin Infect Dis"},{"key":"4096_CR11","doi-asserted-by":"publisher","first-page":"m1328","DOI":"10.1136\/bmj.m1328","volume":"369","author":"L Wynants","year":"2020","unstructured":"Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Bonten MMJ, Dahly DL, Damen JAA, Debray TPA et al (2020) Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ 369:m1328","journal-title":"BMJ"},{"key":"4096_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.addr.2020.12.011","volume":"170","author":"JY Chung","year":"2021","unstructured":"Chung JY, Thone MN, Kwon YJ (2021) COVID-19 vaccines: the status and perspectives in delivery points of view. Adv Drug Deliv Rev 170:1\u201325","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"4096_CR13","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","volume":"184","author":"MS Gebre","year":"2021","unstructured":"Gebre MS, Brito LA, Tostanoski LH, Edwards DK, Carfi A, Barouch DH (2021) Novel approaches for vaccine development. Cell 184(6):1589\u20131603","journal-title":"Cell"},{"issue":"579","key":"4096_CR14","doi-asserted-by":"publisher","first-page":"eabd1525","DOI":"10.1126\/scitranslmed.abd1525","volume":"13","author":"WC Koff","year":"2021","unstructured":"Koff WC, Schenkelberg T, Williams T, Baric RS, McDermott A, Cameron CM, Cameron MJ, Friemann MB, Neumann G, Kawaoka Y et al (2021) Development and deployment of COVID-19 vaccines for those most vulnerable. Sci Transl Med 13(579):eabd1525","journal-title":"Sci Transl Med"},{"key":"4096_CR15","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1056\/NEJMoa2105000","volume":"384","author":"E Hacisuleyman","year":"2021","unstructured":"Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, Schaefer-Babajew DJ, DaSilva J, Muecksch F, Gaebler C et al (2021) Vaccine breakthrough infections with SARS-CoV-2 variants. N Engl J Med 384:2212\u20132218","journal-title":"N Engl J Med"},{"issue":"7855","key":"4096_CR16","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","volume":"592","author":"Z Wang","year":"2021","unstructured":"Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA et al (2021) mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592(7855):616\u2013622","journal-title":"Nature"},{"issue":"4","key":"4096_CR17","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.7150\/thno.53691","volume":"11","author":"TM Karpinski","year":"2021","unstructured":"Karpinski TM, Ozarowski M, Seremak-Mrozikiewicz A, Wolski H, Wlodkowic D (2021) The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics 11(4):1690\u20131702","journal-title":"Theranostics"},{"issue":"10240","key":"4096_CR18","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"F-C Zhu","year":"2020","unstructured":"Zhu F-C, Li Y-H, Guan X-H, Hou L-H, Wang W-J, Li J-X, Wu S-P, Wang B-S, Wang Z, Wang L et al (2020) Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet (London, England) 395(10240):1845\u20131854","journal-title":"Lancet (London, England)"},{"issue":"10249","key":"4096_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA et al (2020) Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet (London, England) 396(10249):467\u2013478","journal-title":"Lancet (London, England)"},{"issue":"7830","key":"4096_CR20","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA et al (2020) Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586(7830):589\u2013593","journal-title":"Nature"},{"issue":"27","key":"4096_CR21","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C et al (2020) Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383(27):2603\u20132615","journal-title":"N Engl J Med"},{"issue":"10287","key":"4096_CR22","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K et al (2021) Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet (London, England) 397(10287):1819\u20131829","journal-title":"Lancet (London, England)"},{"issue":"10269","key":"4096_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE et al (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet (London, England) 397(10269):99\u2013111","journal-title":"Lancet (London, England)"},{"issue":"10267","key":"4096_CR24","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G et al (2021) Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet (London, England) 396(10267):1979\u20131993","journal-title":"Lancet (London, England)"},{"issue":"20","key":"4096_CR25","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","volume":"383","author":"LA Jackson","year":"2020","unstructured":"Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ et al (2020) An mRNA vaccine against SARS-CoV-2\u2014preliminary report. N Engl J Med 383(20):1920\u20131931","journal-title":"N Engl J Med"},{"issue":"5","key":"4096_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 384(5):403\u2013416","journal-title":"N Engl J Med"},{"issue":"24","key":"4096_CR27","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H et al (2020) Phase 1\u20132 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med 383(24):2320\u20132332","journal-title":"N Engl J Med"},{"issue":"20","key":"4096_CR28","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa2103055","volume":"384","author":"V Shinde","year":"2021","unstructured":"Shinde V, Bhikha S, Hoosain Z, Archary M, Bhorat Q, Fairlie L, Lalloo U, Masilela MSL, Moodley D, Hanley S et al (2021) Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med 384(20):1899\u20131909","journal-title":"N Engl J Med"},{"issue":"10275","key":"4096_CR29","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S0140-6736(21)00234-8","volume":"397","author":"DY Logunov","year":"2021","unstructured":"Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS et al (2021) Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet 397(10275):671\u2013681","journal-title":"Lancet"},{"issue":"10249","key":"4096_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0140-6736(20)31605-6","volume":"396","author":"F-C Zhu","year":"2020","unstructured":"Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, Li J-X, Yang B-F, Wang L, Wang W-J et al (2020) Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet (London, England) 396(10249):479\u2013488","journal-title":"Lancet (London, England)"},{"issue":"1","key":"4096_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S1473-3099(20)30831-8","volume":"21","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z et al (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1\/2 trial. Lancet Infect Dis 21(1):39\u201351","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"4096_CR32","doi-asserted-by":"publisher","first-page":"713 e719","DOI":"10.1016\/j.cell.2020.06.008","volume":"182","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J et al (2020) Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182(3):713 e719-721 e719","journal-title":"Cell"},{"issue":"2","key":"4096_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1473-3099(20)30843-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W et al (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis 21(2):181\u2013192","journal-title":"Lancet Infect Dis"},{"key":"4096_CR34","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/S1473-3099(20)30987-7","volume":"21","author":"Z Wu","year":"2021","unstructured":"Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P et al (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis 21:803\u2013812","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"4096_CR35","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P et al (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis 21(5):637\u2013646","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"4096_CR36","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1473-3099(21)00070-0","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S, Das D, Raju D, Praturi U, Sapkal G et al (2021) Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis 21(7):950\u2013961","journal-title":"Lancet Infect Dis"},{"issue":"7","key":"4096_CR37","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1056\/NEJMra2035343","volume":"384","author":"MC Castells","year":"2021","unstructured":"Castells MC, Phillips EJ (2021) Maintaining safety with SARS-CoV-2 vaccines. N Engl J Med 384(7):643\u2013649","journal-title":"N Engl J Med"},{"issue":"2","key":"4096_CR38","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/s41591-020-1124-9","volume":"27","author":"JV Lazarus","year":"2021","unstructured":"Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A (2021) A global survey of potential acceptance of a COVID-19 vaccine. Nat Med 27(2):225\u2013228","journal-title":"Nat Med"},{"issue":"8","key":"4096_CR39","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","volume":"384","author":"P Horby","year":"2021","unstructured":"Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A et al (2021) Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 384(8):693\u2013704","journal-title":"N Engl J Med"},{"issue":"10236","key":"4096_CR40","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","volume":"395","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q et al (2020) Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet (London, England) 395(10236):1569\u20131578","journal-title":"Lancet (London, England)"},{"issue":"10","key":"4096_CR41","first-page":"1192","volume":"6","author":"Q Cai","year":"2020","unstructured":"Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y et al (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 6(10):1192\u20131198","journal-title":"Engineering (Beijing)"},{"issue":"6","key":"4096_CR42","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","volume":"22","author":"J Galipeau","year":"2018","unstructured":"Galipeau J, Sensebe L (2018) Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell 22(6):824\u2013833","journal-title":"Cell Stem Cell"},{"issue":"8","key":"4096_CR43","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3390\/cells8080886","volume":"8","author":"Y Han","year":"2019","unstructured":"Han Y, Li X, Zhang Y, Han Y, Chang F, Ding J (2019) Mesenchymal stem cells for regenerative medicine. Cells 8(8):886","journal-title":"Cells"},{"issue":"4","key":"4096_CR44","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/sctm.20-0213","volume":"10","author":"M Trujillo-Rodriguez","year":"2021","unstructured":"Trujillo-Rodriguez M, Viciana P, Rivas-Jeremias I, Alvarez-Rios AI, Ruiz-Garcia A, Espinosa-Ibanez O, Arias-Santiago S, Martinez-Atienza J, Mata R, Fernandez-Lopez O et al (2021) Mesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: early results of a phase I\/II clinical trial. Stem Cells Transl Med 10(4):534\u2013541","journal-title":"Stem Cells Transl Med"},{"key":"4096_CR45","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3389\/fimmu.2019.01191","volume":"10","author":"ARR Weiss","year":"2019","unstructured":"Weiss ARR, Dahlke MH (2019) Immunomodulation by mesenchymal stem cells (MSCs): mechanisms of action of living, apoptotic, and dead MSCs. Front Immunol 10:1191","journal-title":"Front Immunol"},{"issue":"12","key":"4096_CR46","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/sctm.17-0129","volume":"6","author":"RM Samsonraj","year":"2017","unstructured":"Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM (2017) Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med 6(12):2173\u20132185","journal-title":"Stem Cells Transl Med"},{"issue":"7","key":"4096_CR47","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/stem.3016","volume":"37","author":"A Andrzejewska","year":"2019","unstructured":"Andrzejewska A, Lukomska B, Janowski M (2019) Concise review: mesenchymal stem cells: from roots to boost. Stem Cells 37(7):855\u2013864","journal-title":"Stem Cells"},{"issue":"1","key":"4096_CR48","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s13287-019-1503-7","volume":"10","author":"L Chen","year":"2019","unstructured":"Chen L, Qu J, Cheng T, Chen X, Xiang C (2019) Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem Cell Res Ther 10(1):406","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4096_CR49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cyto.a.23242","volume":"93","author":"D Mushahary","year":"2018","unstructured":"Mushahary D, Spittler A, Kasper C, Weber V, Charwat V (2018) Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytom A 93(1):19\u201331","journal-title":"Cytom A"},{"key":"4096_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1478-811X-9-12","volume":"9","author":"R Hass","year":"2011","unstructured":"Hass R, Kasper C, Bohm S, Jacobs R (2011) Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Cell Commun Signal 9:12","journal-title":"Cell Commun Signal"},{"key":"4096_CR51","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev-cellbio-100913-013132","volume":"30","author":"P Bianco","year":"2014","unstructured":"Bianco P (2014) \u201cMesenchymal\u201d stem cells. Annu Rev Cell Dev Biol 30:677\u2013704","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"9","key":"4096_CR52","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nri2395","volume":"8","author":"A Uccelli","year":"2008","unstructured":"Uccelli A, Moretta L, Pistoia V (2008) Mesenchymal stem cells in health and disease. Nat Rev Immunol 8(9):726\u2013736","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"4096_CR53","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41551-018-0325-8","volume":"3","author":"JQ Yin","year":"2019","unstructured":"Yin JQ, Zhu J, Ankrum JA (2019) Manufacturing of primed mesenchymal stromal cells for therapy. Nat Biomed Eng 3(2):90\u2013104","journal-title":"Nat Biomed Eng"},{"issue":"3","key":"4096_CR54","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jcyt.2018.01.009","volume":"20","author":"K Le Blanc","year":"2018","unstructured":"Le Blanc K, Davies LC (2018) MSCs\u2014cells with many sides. Cytotherapy 20(3):273\u2013278","journal-title":"Cytotherapy"},{"issue":"14","key":"4096_CR55","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1007\/s00018-020-03454-6","volume":"77","author":"XL Fan","year":"2020","unstructured":"Fan XL, Zhang Y, Li X, Fu QL (2020) Mechanisms underlying the protective effects of mesenchymal stem cell-based therapy. Cell Mol Life Sci 77(14):2771\u20132794","journal-title":"Cell Mol Life Sci"},{"issue":"5","key":"4096_CR56","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nri3209","volume":"12","author":"K Le Blanc","year":"2012","unstructured":"Le Blanc K, Mougiakakos D (2012) Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 12(5):383\u2013396","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"4096_CR57","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","volume":"41","author":"N Song","year":"2020","unstructured":"Song N, Scholtemeijer M, Shah K (2020) Mesenchymal stem cell immunomodulation: mechanisms and therapeutic potential. Trends Pharmacol Sci 41(9):653\u2013664","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"4096_CR58","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s13287-020-01855-9","volume":"11","author":"X Wu","year":"2020","unstructured":"Wu X, Jiang J, Gu Z, Zhang J, Chen Y, Liu X (2020) Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress. Stem Cell Res Ther 11(1):345","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"4096_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/sctm.19-0202","volume":"9","author":"M Kabat","year":"2020","unstructured":"Kabat M, Bobkov I, Kumar S, Grumet M (2020) Trends in mesenchymal stem cell clinical trials 2004\u20132018: is efficacy optimal in a narrow dose range? Stem Cells Transl Med 9(1):17\u201327","journal-title":"Stem Cells Transl Med"},{"issue":"11","key":"4096_CR60","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/sctm.19-0044","volume":"8","author":"I Mastrolia","year":"2019","unstructured":"Mastrolia I, Foppiani EM, Murgia A, Candini O, Samarelli AV, Grisendi G, Veronesi E, Horwitz EM, Dominici M (2019) Challenges in clinical development of mesenchymal stromal\/stem cells: concise review. Stem Cells Transl Med 8(11):1135\u20131148","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"4096_CR61","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","volume":"3","author":"JG Wilson","year":"2015","unstructured":"Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, Cosgrove K, Vojnik R, Calfee CS, Lee J-W et al (2015) Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3(1):24\u201332","journal-title":"Lancet Respir Med"},{"issue":"10","key":"4096_CR62","first-page":"1153","volume":"6","author":"J Chen","year":"2020","unstructured":"Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, Chen L, Gao H, Lu X, Yu L et al (2020) Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID-19 treatment. Engineering (Beijing) 6(10):1153\u20131161","journal-title":"Engineering (Beijing)"},{"issue":"2","key":"4096_CR63","doi-asserted-by":"publisher","first-page":"281 e286","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181(2):281 e286-292 e286","journal-title":"Cell"},{"issue":"1","key":"4096_CR64","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1038\/s41467-020-18319-6","volume":"11","author":"J Yang","year":"2020","unstructured":"Yang J, Petitjean SJL, Koehler M, Zhang Q, Dumitru AC, Chen W, Derclaye S, Vincent SP, Soumillion P, Alsteens D (2020) Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. Nat Commun 11(1):4541","journal-title":"Nat Commun"},{"issue":"3","key":"4096_CR65","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.stemcr.2020.09.003","volume":"16","author":"R Schafer","year":"2021","unstructured":"Schafer R, Spohn G, Bechtel M, Bojkova D, Baer PC, Kuci S, Seifried E, Ciesek S, Cinatl J (2021) Human mesenchymal stromal cells are resistant to SARS-CoV-2 infection under steady-state, inflammatory conditions and in the presence of SARS-CoV-2-infected cells. Stem Cell Rep 16(3):419\u2013427","journal-title":"Stem Cell Rep"},{"issue":"4","key":"4096_CR66","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1002\/sctm.20-0385","volume":"10","author":"MA Avanzini","year":"2021","unstructured":"Avanzini MA, Mura M, Percivalle E, Bastaroli F, Croce S, Valsecchi C, Lenta E, Nykjaer G, Cassaniti I, Bagnarino J et al (2021) Human mesenchymal stromal cells do not express ACE2 and TMPRSS2 and are not permissive to SARS-CoV-2 infection. Stem Cells Transl Med 10(4):636\u2013642","journal-title":"Stem Cells Transl Med"},{"key":"4096_CR67","doi-asserted-by":"publisher","first-page":"100694","DOI":"10.1016\/j.cegh.2020.100694","volume":"10","author":"B Ganesh","year":"2021","unstructured":"Ganesh B, Rajakumar T, Malathi M, Manikandan N, Nagaraj J, Santhakumar A, Elangovan A, Malik YS (2021) Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives. Clin Epidemiol Glob Health 10:100694","journal-title":"Clin Epidemiol Glob Health"},{"issue":"8","key":"4096_CR68","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.7150\/thno.55647","volume":"11","author":"BK Park","year":"2021","unstructured":"Park BK, Kim J, Park S, Kim D, Kim M, Baek K, Bae JY, Park MS, Kim WK, Lee Y et al (2021) MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein. Theranostics 11(8):3853\u20133867","journal-title":"Theranostics"},{"issue":"3","key":"4096_CR69","doi-asserted-by":"publisher","first-page":"e2106","DOI":"10.1002\/rmv.2106","volume":"30","author":"Y Yan","year":"2020","unstructured":"Yan Y, Chang L, Wang L (2020) Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): current status, challenges, and countermeasures. Rev Med Virol 30(3):e2106","journal-title":"Rev Med Virol"},{"issue":"3","key":"4096_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V'Kovski","year":"2021","unstructured":"V\u2019Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V (2021) Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol 19(3):155\u2013170","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"4096_CR71","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41421-020-00231-4","volume":"6","author":"F Wang","year":"2020","unstructured":"Wang F, Huang S, Gao R, Zhou Y, Lai C, Li Z, Xian W, Qian X, Li Z, Huang Y et al (2020) Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov 6(1):83","journal-title":"Cell Discov"},{"issue":"10224","key":"4096_CR72","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet (London, England) 395(10224):565\u2013574","journal-title":"Lancet (London, England)"},{"issue":"5748","key":"4096_CR73","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1126\/science.1118391","volume":"310","author":"W Li","year":"2005","unstructured":"Li W, Shi Z, Yu M, Ren W, Smith C, Epstein JH, Wang H, Crameri G, Hu Z, Zhang H et al (2005) Bats are natural reservoirs of SARS-like coronaviruses. Science (New York, NY) 310(5748):676\u2013679","journal-title":"Science (New York, NY)"},{"key":"4096_CR74","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12985-016-0544-0","volume":"13","author":"HA Mohd","year":"2016","unstructured":"Mohd HA, Al-Tawfiq JA, Memish ZA (2016) Middle East Respiratory Syndrome Coronavirus (MERS-CoV) origin and animal reservoir. Virol J 13:87","journal-title":"Virol J"},{"issue":"13","key":"4096_CR75","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, Ren R, Leung KSM, Lau EHY, Wong JY et al (2020) Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 382(13):1199\u20131207","journal-title":"N Engl J Med"},{"issue":"7798","key":"4096_CR76","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270\u2013273","journal-title":"Nature"},{"issue":"12","key":"4096_CR77","doi-asserted-by":"publisher","first-page":"e3001016","DOI":"10.1371\/journal.pbio.3001016","volume":"18","author":"C Conceicao","year":"2020","unstructured":"Conceicao C, Thakur N, Human S, Kelly JT, Logan L, Bialy D, Bhat S, Stevenson-Leggett P, Zagrajek AK, Hollinghurst P et al (2020) The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins. PLoS Biol 18(12):e3001016","journal-title":"PLoS Biol"},{"issue":"7815","key":"4096_CR78","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41586-020-2169-0","volume":"583","author":"TT Lam","year":"2020","unstructured":"Lam TT, Jia N, Zhang YW, Shum MH, Jiang JF, Zhu HC, Tong YG, Shi YX, Ni XB, Liao YS et al (2020) Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. Nature 583(7815):282\u2013285","journal-title":"Nature"},{"issue":"7815","key":"4096_CR79","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41586-020-2313-x","volume":"583","author":"K Xiao","year":"2020","unstructured":"Xiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou JJ, Li N, Guo Y, Li X, Shen X et al (2020) Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature 583(7815):286\u2013289","journal-title":"Nature"},{"issue":"6525","key":"4096_CR80","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1126\/science.abe5901","volume":"371","author":"BB Oude Munnink","year":"2021","unstructured":"Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, Molenaar RJ, Munger E, Molenkamp R, van der Spek A, Tolsma P, Rietveld A, Brouwer M et al (2021) Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. Science (New York, NY) 371(6525):172\u2013177","journal-title":"Science (New York, NY)"},{"issue":"1","key":"4096_CR81","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.1038\/s41467-020-20097-0","volume":"11","author":"EI Patterson","year":"2020","unstructured":"Patterson EI, Elia G, Grassi A, Giordano A, Desario C, Medardo M, Smith SL, Anderson ER, Prince T, Patterson GT et al (2020) Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy. Nat Commun 11(1):6231","journal-title":"Nat Commun"},{"issue":"40","key":"4096_CR82","doi-asserted-by":"publisher","first-page":"24790","DOI":"10.1073\/pnas.2010817117","volume":"117","author":"J Segales","year":"2020","unstructured":"Segales J, Puig M, Rodon J, Avila-Nieto C, Carrillo J, Cantero G, Terron MT, Cruz S, Parera M, Noguera-Julian M et al (2020) Detection of SARS-CoV-2 in a cat owned by a COVID-19-affected patient in Spain. Proc Natl Acad Sci USA 117(40):24790\u201324793","journal-title":"Proc Natl Acad Sci USA"},{"issue":"16","key":"4096_CR83","doi-asserted-by":"publisher","first-page":"5953","DOI":"10.1007\/s00018-021-03889-5","volume":"78","author":"S Boutin","year":"2021","unstructured":"Boutin S, Hildebrand D, Boulant S, Kreuter M, Ruter J, Pallerla SR, Velavan TP, Nurjadi D (2021) Host factors facilitating SARS-CoV-2 virus infection and replication in the lungs. Cell Mol Life Sci 78(16):5953\u20135976","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"4096_CR84","doi-asserted-by":"publisher","first-page":"1043 e1015","DOI":"10.1016\/j.cell.2020.09.033","volume":"183","author":"TM Clausen","year":"2020","unstructured":"Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, Narayanan A, Majowicz SA, Kwong EM, McVicar RN et al (2020) SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 183(4):1043 e1015-1057 e1015","journal-title":"Cell"},{"issue":"10","key":"4096_CR85","doi-asserted-by":"publisher","first-page":"e105114","DOI":"10.15252\/embj.2020105114","volume":"39","author":"S Lukassen","year":"2020","unstructured":"Lukassen S, Chua RL, Trefzer T, Kahn NC, Schneider MA, Muley T, Winter H, Meister M, Veith C, Boots AW et al (2020) SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J 39(10):e105114","journal-title":"EMBO J"},{"issue":"2","key":"4096_CR86","doi-asserted-by":"publisher","first-page":"271 e278","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):271 e278-280 e278","journal-title":"Cell"},{"issue":"4","key":"4096_CR87","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s00018-020-03580-1","volume":"78","author":"I Mercurio","year":"2021","unstructured":"Mercurio I, Tragni V, Busto F, De Grassi A, Pierri CL (2021) Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies. Cell Mol Life Sci 78(4):1501\u20131522","journal-title":"Cell Mol Life Sci"},{"key":"4096_CR88","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1146\/annurev-pathmechdis-012419-032847","volume":"15","author":"J Zindel","year":"2020","unstructured":"Zindel J, Kubes P (2020) DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation. Annu Rev Pathol 15:493\u2013518","journal-title":"Annu Rev Pathol"},{"key":"4096_CR89","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3389\/fimmu.2014.00491","volume":"5","author":"G Arango Duque","year":"2014","unstructured":"Arango Duque G, Descoteaux A (2014) Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol 5:491","journal-title":"Front Immunol"},{"issue":"2","key":"4096_CR90","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/jctb.6641","volume":"96","author":"V Kumar","year":"2021","unstructured":"Kumar V, Doshi KU, Khan WH, Rathore AS (2021) COVID-19 pandemic: mechanism, diagnosis, and treatment. J Chem Technol Biotechnol 96(2):299\u2013308","journal-title":"J Chem Technol Biotechnol"},{"issue":"8","key":"4096_CR91","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/s41591-020-0965-6","volume":"26","author":"QX Long","year":"2020","unstructured":"Long QX, Tang XJ, Shi QL, Li Q, Deng HJ, Yuan J, Hu JL, Xu W, Zhang Y, Lv FJ et al (2020) Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat Med 26(8):1200\u20131204","journal-title":"Nat Med"},{"issue":"7848","key":"4096_CR92","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41586-020-03065-y","volume":"591","author":"E Pairo-Castineira","year":"2021","unstructured":"Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD et al (2021) Genetic mechanisms of critical illness in COVID-19. Nature 591(7848):92\u201398","journal-title":"Nature"},{"issue":"10223","key":"4096_CR93","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","volume":"395","author":"N Chen","year":"2020","unstructured":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 395(10223):507\u2013513","journal-title":"Lancet (London, England)"},{"issue":"9","key":"4096_CR94","doi-asserted-by":"publisher","first-page":"577","DOI":"10.7326\/M20-0504","volume":"172","author":"SA Lauer","year":"2020","unstructured":"Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J (2020) The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 172(9):577\u2013582","journal-title":"Ann Intern Med"},{"issue":"7","key":"4096_CR95","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S2213-2600(20)30243-5","volume":"8","author":"SE Fox","year":"2020","unstructured":"Fox SE, Akmatbekov A, Harbert JL, Li G, Quincy Brown J, Vander Heide RS (2020) Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. Lancet Respir Med 8(7):681\u2013686","journal-title":"Lancet Respir Med"},{"issue":"4","key":"4096_CR96","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","volume":"8","author":"Z Xu","year":"2020","unstructured":"Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L et al (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8(4):420\u2013422","journal-title":"Lancet Respir Med"},{"issue":"1","key":"4096_CR97","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.chest.2020.09.259","volume":"159","author":"LP Hariri","year":"2021","unstructured":"Hariri LP, North CM, Shih AR, Israel RA, Maley JH, Villalba JA, Vinarsky V, Rubin J, Okin DA, Sclafani A et al (2021) Lung histopathology in coronavirus disease 2019 as compared with severe acute respiratory syndrome and H1N1 influenza: a systematic review. Chest 159(1):73\u201384","journal-title":"Chest"},{"key":"4096_CR98","doi-asserted-by":"publisher","first-page":"m606","DOI":"10.1136\/bmj.m606","volume":"368","author":"X-W Xu","year":"2020","unstructured":"Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, Li S-B, Wang H-Y, Zhang S, Gao H-N et al (2020) Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ 368:m606","journal-title":"BMJ"},{"issue":"4","key":"4096_CR99","doi-asserted-by":"publisher","first-page":"e158","DOI":"10.1002\/ctm2.158","volume":"10","author":"M Xu","year":"2020","unstructured":"Xu M, Wang D, Wang H, Zhang X, Liang T, Dai J, Li M, Zhang J, Zhang K, Xu D et al (2020) COVID-19 diagnostic testing: technology perspective. Clin Transl Med 10(4):e158","journal-title":"Clin Transl Med"},{"issue":"8","key":"4096_CR100","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC (2020) Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA 324(8):782\u2013793","journal-title":"JAMA"},{"issue":"1","key":"4096_CR101","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41392-021-00508-4","volume":"6","author":"Y Li","year":"2021","unstructured":"Li Y, Hou G, Zhou H, Wang Y, Tun HM, Zhu A, Zhao J, Xiao F, Lin S, Liu D et al (2021) Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery. Signal Transduct Target Ther 6(1):155","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4096_CR102","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1038\/s41467-021-24482-1","volume":"12","author":"P Wu","year":"2021","unstructured":"Wu P, Chen D, Ding W, Wu P, Hou H, Bai Y, Zhou Y, Li K, Xiang S, Liu P et al (2021) The trans-omics landscape of COVID-19. Nat Commun 12(1):4543","journal-title":"Nat Commun"},{"issue":"9","key":"4096_CR103","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/CCM.0000000000004447","volume":"48","author":"X Yang","year":"2020","unstructured":"Yang X, Cai S, Luo Y, Zhu F, Hu M, Zhao Y, Zheng R, Li X, Hu B, Peng Z (2020) Extracorporeal membrane oxygenation for coronavirus disease 2019-induced acute respiratory distress syndrome: a multicenter descriptive study. Crit Care Med 48(9):1289\u20131295","journal-title":"Crit Care Med"},{"issue":"9","key":"4096_CR104","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1172\/JCI140200","volume":"130","author":"MJ Joyner","year":"2020","unstructured":"Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, Carter RE, Klompas AM, Wiggins CC, Shepherd JR et al (2020) Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Investig 130(9):4791\u20134797","journal-title":"J Clin Investig"},{"issue":"8","key":"4096_CR105","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-020-0732-3","volume":"15","author":"HF Florindo","year":"2020","unstructured":"Florindo HF, Kleiner R, Vaskovich-Koubi D, Acurcio RC, Carreira B, Yeini E, Tiram G, Liubomirski Y, Satchi-Fainaro R (2020) Immune-mediated approaches against COVID-19. Nat Nanotechnol 15(8):630\u2013645","journal-title":"Nat Nanotechnol"},{"issue":"7","key":"4096_CR106","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.apsb.2020.06.009","volume":"10","author":"L Ni","year":"2020","unstructured":"Ni L, Chen L, Huang X, Han C, Xu J, Zhang H, Luan X, Zhao Y, Xu J, Yuan W et al (2020) Combating COVID-19 with integrated traditional Chinese and Western medicine in China. Acta Pharm Sin B 10(7):1149\u20131162","journal-title":"Acta Pharm Sin B"},{"key":"4096_CR107","doi-asserted-by":"publisher","first-page":"632677","DOI":"10.3389\/fphar.2021.632677","volume":"12","author":"O Indari","year":"2021","unstructured":"Indari O, Jakhmola S, Manivannan E, Jha HC (2021) An update on antiviral therapy against SARS-CoV-2: how far have we come? Front Pharmacol 12:632677","journal-title":"Front Pharmacol"},{"issue":"1","key":"4096_CR108","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s12015-020-10017-6","volume":"17","author":"D Esquivel","year":"2021","unstructured":"Esquivel D, Mishra R, Soni P, Seetharaman R, Mahmood A, Srivastava A (2021) Stem cells therapy as a possible therapeutic option in treating COVID-19 patients. Stem Cell Rev Rep 17(1):144\u2013152","journal-title":"Stem Cell Rev Rep"},{"issue":"574","key":"4096_CR109","doi-asserted-by":"publisher","first-page":"eabe4282","DOI":"10.1126\/scitranslmed.abe4282","volume":"12","author":"A Bharat","year":"2020","unstructured":"Bharat A, Querrey M, Markov NS, Kim S, Kurihara C, Garza-Castillon R, Manerikar A, Shilatifard A, Tomic R, Politanska Y et al (2020) Lung transplantation for patients with severe COVID-19. Sci Transl Med 12(574):eabe4282","journal-title":"Sci Transl Med"},{"issue":"1","key":"4096_CR110","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41392-020-0127-9","volume":"5","author":"W Zhou","year":"2020","unstructured":"Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, Hu M, Fang M, Gao Y (2020) Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther 5(1):18","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"4096_CR111","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/v13020202","volume":"13","author":"A Sharma","year":"2021","unstructured":"Sharma A, Ahmad Farouk I, Lal SK (2021) COVID-19: a review on the novel coronavirus disease evolution, transmission, detection, control and prevention. Viruses 13(2):202","journal-title":"Viruses"},{"issue":"5","key":"4096_CR112","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.molmed.2020.02.008","volume":"26","author":"J Sun","year":"2020","unstructured":"Sun J, He WT, Wang L, Lai A, Ji X, Zhai X, Li G, Suchard MA, Tian J, Zhou J et al (2020) COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med 26(5):483\u2013495","journal-title":"Trends Mol Med"},{"key":"4096_CR113","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","volume":"4","author":"MF Pittenger","year":"2019","unstructured":"Pittenger MF, Discher DE, Peault BM, Phinney DG, Hare JM, Caplan AI (2019) Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med 4:22","journal-title":"NPJ Regen Med"},{"issue":"3","key":"4096_CR114","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3390\/jcm9030682","volume":"9","author":"J Behnke","year":"2020","unstructured":"Behnke J, Kremer S, Shahzad T, Chao CM, Bottcher-Friebertshauser E, Morty RE, Bellusci S, Ehrhardt H (2020) MSC based therapies-new perspectives for the injured lung. J Clin Med 9(3):682","journal-title":"J Clin Med"},{"key":"4096_CR115","doi-asserted-by":"publisher","first-page":"4236973","DOI":"10.1155\/2019\/4236973","volume":"2019","author":"CR Harrell","year":"2019","unstructured":"Harrell CR, Sadikot R, Pascual J, Fellabaum C, Jankovic MG, Jovicic N, Djonov V, Arsenijevic N, Volarevic V (2019) Mesenchymal stem cell-based therapy of inflammatory lung diseases: current understanding and future perspectives. Stem Cells Int 2019:4236973","journal-title":"Stem Cells Int"},{"issue":"4","key":"4096_CR116","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1378\/chest.10-0518","volume":"138","author":"MA Matthay","year":"2010","unstructured":"Matthay MA, Thompson BT, Read EJ, McKenna DH Jr, Liu KD, Calfee CS, Lee JW (2010) Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest 138(4):965\u2013972","journal-title":"Chest"},{"issue":"2","key":"4096_CR117","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/infdis\/jiy478","volume":"219","author":"H Loy","year":"2019","unstructured":"Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, Peiris JSM, Chan MCW (2019) Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A (H5N1) virus-associated acute lung injury. J Infect Dis 219(2):186\u2013196","journal-title":"J Infect Dis"},{"issue":"10","key":"4096_CR118","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/s41419-020-03036-1","volume":"11","author":"J Zhu","year":"2020","unstructured":"Zhu J, Feng B, Xu Y, Chen W, Sheng X, Feng X, Shi X, Liu J, Pan Q, Yu J et al (2020) Mesenchymal stem cells alleviate LPS-induced acute lung injury by inhibiting the proinflammatory function of Ly6C(+) CD8(+) T cells. Cell Death Dis 11(10):829","journal-title":"Cell Death Dis"},{"issue":"2","key":"4096_CR119","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1164\/rccm.201207-1204PP","volume":"188","author":"RL Toonkel","year":"2013","unstructured":"Toonkel RL, Hare JM, Matthay MA, Glassberg MK (2013) Mesenchymal stem cells and idiopathic pulmonary fibrosis. Potential for clinical testing. Am J Respir Crit Care Med 188(2):133\u2013140","journal-title":"Am J Respir Crit Care Med"},{"key":"4096_CR120","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fmed.2018.00142","volume":"5","author":"A Tzouvelekis","year":"2018","unstructured":"Tzouvelekis A, Toonkel R, Karampitsakos T, Medapalli K, Ninou I, Aidinis V, Bouros D, Glassberg MK (2018) Mesenchymal stem cells for the treatment of idiopathic pulmonary fibrosis. Front Med (Lausanne) 5:142","journal-title":"Front Med (Lausanne)"},{"key":"4096_CR121","doi-asserted-by":"publisher","first-page":"639657","DOI":"10.3389\/fcell.2021.639657","volume":"9","author":"S Yang","year":"2021","unstructured":"Yang S, Liu P, Jiang Y, Wang Z, Dai H, Wang C (2021) Therapeutic applications of mesenchymal stem cells in idiopathic pulmonary fibrosis. Front Cell Dev Biol 9:639657","journal-title":"Front Cell Dev Biol"},{"key":"4096_CR122","doi-asserted-by":"publisher","first-page":"5432134","DOI":"10.1155\/2019\/5432134","volume":"2019","author":"J Han","year":"2019","unstructured":"Han J, Li Y, Li Y (2019) Strategies to enhance mesenchymal stem cell-based therapies for acute respiratory distress syndrome. Stem Cells Int 2019:5432134","journal-title":"Stem Cells Int"},{"issue":"10","key":"4096_CR123","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s13238-020-00738-2","volume":"11","author":"H Qin","year":"2020","unstructured":"Qin H, Zhao A (2020) Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics. Protein Cell 11(10):707\u2013722","journal-title":"Protein Cell"},{"key":"4096_CR124","first-page":"1939768","volume":"2020","author":"CR Harrell","year":"2020","unstructured":"Harrell CR, Jovicic BP, Djonov V, Volarevic V (2020) Therapeutic potential of mesenchymal stem cells and their secretome in the treatment of SARS-CoV-2-induced acute respiratory distress syndrome. Anal Cell Pathol (Amst) 2020:1939768","journal-title":"Anal Cell Pathol (Amst)"},{"key":"4096_CR125","doi-asserted-by":"publisher","first-page":"6294717","DOI":"10.1155\/2017\/6294717","volume":"2017","author":"M Gazdic","year":"2017","unstructured":"Gazdic M, Simovic Markovic B, Jovicic N, Misirkic-Marjanovic M, Djonov V, Jakovljevic V, Arsenijevic N, Lukic ML, Volarevic V (2017) Mesenchymal stem cells promote metastasis of lung cancer cells by downregulating systemic antitumor immune response. Stem Cells Int 2017:6294717","journal-title":"Stem Cells Int"},{"key":"4096_CR126","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2018.10.017","volume":"440\u2013441","author":"PY Jung","year":"2019","unstructured":"Jung PY, Ryu H, Rhee KJ, Hwang S, Lee CG, Gwon SY, Kim J, Kim J, Yoo BS, Baik SK et al (2019) Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-beta and TRAIL and suppress the growth of H460 human lung cancer cells. Cancer Lett 440\u2013441:202\u2013210","journal-title":"Cancer Lett"},{"issue":"6","key":"4096_CR127","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s13402-019-00459-7","volume":"42","author":"L Cortes-Dericks","year":"2019","unstructured":"Cortes-Dericks L, Galetta D (2019) The therapeutic potential of mesenchymal stem cells in lung cancer: benefits, risks and challenges. Cell Oncol (Dordr) 42(6):727\u2013738","journal-title":"Cell Oncol (Dordr)"},{"issue":"6","key":"4096_CR128","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/all.12392","volume":"69","author":"L Marinas-Pardo","year":"2014","unstructured":"Marinas-Pardo L, Mirones I, Amor-Carro O, Fraga-Iriso R, Lema-Costa B, Cubillo I, Rodriguez Milla MA, Garcia-Castro J, Ramos-Barbon D (2014) Mesenchymal stem cells regulate airway contractile tissue remodeling in murine experimental asthma. Allergy 69(6):730\u2013740","journal-title":"Allergy"},{"issue":"2","key":"4096_CR129","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/sctm.19-0120","volume":"9","author":"LL Castro","year":"2020","unstructured":"Castro LL, Kitoko JZ, Xisto DG, Olsen PC, Guedes HLM, Morales MM, Lopes-Pacheco M, Cruz FF, Rocco PRM (2020) Multiple doses of adipose tissue-derived mesenchymal stromal cells induce immunosuppression in experimental asthma. Stem Cells Transl Med 9(2):250\u2013260","journal-title":"Stem Cells Transl Med"},{"key":"4096_CR130","doi-asserted-by":"publisher","first-page":"8733","DOI":"10.1038\/srep08733","volume":"5","author":"W Gu","year":"2015","unstructured":"Gu W, Song L, Li XM, Wang D, Guo XJ, Xu WG (2015) Mesenchymal stem cells alleviate airway inflammation and emphysema in COPD through down-regulation of cyclooxygenase-2 via p38 and ERK MAPK pathways. Sci Rep 5:8733","journal-title":"Sci Rep"},{"key":"4096_CR131","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.reth.2019.07.009","volume":"11","author":"JW Cho","year":"2019","unstructured":"Cho JW, Park KS, Bae JY (2019) Effects of Wharton\u2019s jelly-derived mesenchymal stem cells on chronic obstructive pulmonary disease. Regen Ther 11:207\u2013211","journal-title":"Regen Ther"},{"issue":"2","key":"4096_CR132","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S2213-2600(18)30418-1","volume":"7","author":"MA Matthay","year":"2019","unstructured":"Matthay MA, Calfee CS, Zhuo H, Thompson BT, Wilson JG, Levitt JE, Rogers AJ, Gotts JE, Wiener-Kronish JP, Bajwa EK et al (2019) Treatment with allogeneic mesenchymal stromal cells for moderate to severe acute respiratory distress syndrome (START study): a randomised phase 2a safety trial. Lancet Respir Med 7(2):154\u2013162","journal-title":"Lancet Respir Med"},{"issue":"10","key":"4096_CR133","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/sctm.20-0186","volume":"9","author":"BL Yen","year":"2020","unstructured":"Yen BL, Yen ML, Wang LT, Liu KJ, Sytwu HK (2020) Current status of mesenchymal stem cell therapy for immune\/inflammatory lung disorders: Gleaning insights for possible use in COVID-19. Stem Cells Transl Med 9(10):1163\u20131173","journal-title":"Stem Cells Transl Med"},{"issue":"8","key":"4096_CR134","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3109\/01902148.2013.816803","volume":"39","author":"AC Inamdar","year":"2013","unstructured":"Inamdar AC, Inamdar AA (2013) Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell. Exp Lung Res 39(8):315\u2013327","journal-title":"Exp Lung Res"},{"key":"4096_CR135","doi-asserted-by":"publisher","first-page":"118493","DOI":"10.1016\/j.lfs.2020.118493","volume":"262","author":"S Sadeghi","year":"2020","unstructured":"Sadeghi S, Soudi S, Shafiee A, Hashemi SM (2020) Mesenchymal stem cell therapies for COVID-19: current status and mechanism of action. Life Sci 262:118493","journal-title":"Life Sci"},{"issue":"3","key":"4096_CR136","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12015-020-09973-w","volume":"16","author":"A Golchin","year":"2020","unstructured":"Golchin A, Seyedjafari E, Ardeshirylajimi A (2020) Mesenchymal stem cell therapy for COVID-19: present or future. Stem Cell Rev Rep 16(3):427\u2013433","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"4096_CR137","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41536-020-00105-z","volume":"5","author":"N Durand","year":"2020","unstructured":"Durand N, Mallea J, Zubair AC (2020) Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure. Npj Regen Med 5(1):17","journal-title":"Npj Regen Med"},{"key":"4096_CR138","doi-asserted-by":"publisher","first-page":"963689721995455","DOI":"10.1177\/0963689721995455","volume":"30","author":"J Xiong","year":"2021","unstructured":"Xiong J, Chen L, Zhang L, Bao L, Shi Y (2021) Mesenchymal stromal cell-based therapy: a promising approach for severe COVID-19. Cell Transplant 30:963689721995455","journal-title":"Cell Transplant"},{"issue":"1\u20132","key":"4096_CR139","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.diff.2016.02.005","volume":"92","author":"SG Almalki","year":"2016","unstructured":"Almalki SG, Agrawal DK (2016) Key transcription factors in the differentiation of mesenchymal stem cells. Differentiation 92(1\u20132):41\u201351","journal-title":"Differentiation"},{"issue":"12","key":"4096_CR140","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1042\/CBI20110026","volume":"35","author":"N Ma","year":"2011","unstructured":"Ma N, Gai H, Mei J, Ding FB, Bao CR, Nguyen DM, Zhong H (2011) Bone marrow mesenchymal stem cells can differentiate into type II alveolar epithelial cells in vitro. Cell Biol Int 35(12):1261\u20131266","journal-title":"Cell Biol Int"},{"issue":"13","key":"4096_CR141","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1089\/scd.2020.0208","volume":"30","author":"J Liu","year":"2021","unstructured":"Liu J, Peng D, You J, Zhou O, Qiu H, Hao C, Chen H, Fu Z, Zou L (2021) Type 2 alveolar epithelial cells differentiated from human umbilical cord mesenchymal stem cells alleviate mouse pulmonary fibrosis through beta-catenin-regulated cell apoptosis. Stem Cells Dev 30(13):660\u2013670","journal-title":"Stem Cells Dev"},{"key":"4096_CR142","doi-asserted-by":"publisher","first-page":"118588","DOI":"10.1016\/j.lfs.2020.118588","volume":"263","author":"P Yadav","year":"2020","unstructured":"Yadav P, Vats R, Bano A, Bhardwaj R (2020) Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics. Life Sci 263:118588","journal-title":"Life Sci"},{"issue":"8","key":"4096_CR143","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41581-018-0023-5","volume":"14","author":"Y Shi","year":"2018","unstructured":"Shi Y, Wang Y, Li Q, Liu K, Hou J, Shao C, Wang Y (2018) Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol 14(8):493\u2013507","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"4096_CR144","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","volume":"184","author":"A Sette","year":"2021","unstructured":"Sette A, Crotty S (2021) Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184(4):861\u2013880","journal-title":"Cell"},{"key":"4096_CR145","doi-asserted-by":"publisher","first-page":"102763","DOI":"10.1016\/j.ebiom.2020.102763","volume":"55","author":"J Liu","year":"2020","unstructured":"Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L et al (2020) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55:102763","journal-title":"EBioMedicine"},{"issue":"9","key":"4096_CR146","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.3727\/096368913X667709","volume":"23","author":"X Liang","year":"2014","unstructured":"Liang X, Ding Y, Zhang Y, Tse HF, Lian Q (2014) Paracrine mechanisms of mesenchymal stem cell-based therapy: current status and perspectives. Cell Transplant 23(9):1045\u20131059","journal-title":"Cell Transplant"},{"issue":"7","key":"4096_CR147","doi-asserted-by":"publisher","first-page":"e2001689","DOI":"10.1002\/adhm.202001689","volume":"10","author":"C Chang","year":"2021","unstructured":"Chang C, Yan J, Yao Z, Zhang C, Li X, Mao HQ (2021) Effects of mesenchymal stem cell-derived paracrine signals and their delivery strategies. Adv Healthc Mater 10(7):e2001689","journal-title":"Adv Healthc Mater"},{"issue":"12","key":"4096_CR148","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.molmed.2020.09.012","volume":"26","author":"SS Cabler","year":"2020","unstructured":"Cabler SS, French AR, Orvedahl A (2020) A cytokine circus with a viral ringleader: SARS-CoV-2-associated cytokine storm syndromes. Trends Mol Med 26(12):1078\u20131085","journal-title":"Trends Mol Med"},{"issue":"1","key":"4096_CR149","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","volume":"53","author":"N Mangalmurti","year":"2020","unstructured":"Mangalmurti N, Hunter CA (2020) Cytokine storms: understanding COVID-19. Immunity 53(1):19\u201325","journal-title":"Immunity"},{"issue":"1","key":"4096_CR150","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s12015-020-10037-2","volume":"17","author":"YK Verma","year":"2021","unstructured":"Verma YK, Verma R, Tyagi N, Behl A, Kumar S, Gangenahalli GU (2021) COVID-19 and its therapeutics: special emphasis on mesenchymal stem cells based therapy. Stem Cell Rev Rep 17(1):113\u2013131","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"4096_CR151","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1186\/s13287-020-02028-4","volume":"11","author":"J Obendorf","year":"2020","unstructured":"Obendorf J, Fabian C, Thome UH, Laube M (2020) Paracrine stimulation of perinatal lung functional and structural maturation by mesenchymal stem cells. Stem Cell Res Ther 11(1):525","journal-title":"Stem Cell Res Ther"},{"key":"4096_CR152","doi-asserted-by":"publisher","first-page":"602183","DOI":"10.3389\/fcvm.2020.602183","volume":"7","author":"GM Ellison-Hughes","year":"2020","unstructured":"Ellison-Hughes GM, Colley L, O\u2019Brien KA, Roberts KA, Agbaedeng TA, Ross MD (2020) The Role of MSC therapy in attenuating the damaging effects of the cytokine storm induced by COVID-19 on the heart and cardiovascular system. Front Cardiovasc Med 7:602183","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"4096_CR153","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3390\/ijms18040689","volume":"18","author":"B Xiang","year":"2017","unstructured":"Xiang B, Chen L, Wang X, Zhao Y, Wang Y, Xiang C (2017) Transplantation of menstrual blood-derived mesenchymal stem cells promotes the repair of LPS-induced acute lung injury. Int J Mol Sci 18(4):689","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4096_CR154","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1186\/s13287-020-01926-x","volume":"11","author":"X Chen","year":"2020","unstructured":"Chen X, Wu Y, Wang Y, Chen L, Zheng W, Zhou S, Xu H, Li Y, Yuan L, Xiang C (2020) Human menstrual blood-derived stem cells mitigate bleomycin-induced pulmonary fibrosis through anti-apoptosis and anti-inflammatory effects. Stem Cell Res Ther 11(1):477","journal-title":"Stem Cell Res Ther"},{"issue":"3","key":"4096_CR155","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.stem.2009.02.001","volume":"4","author":"JM Karp","year":"2009","unstructured":"Karp JM, Leng Teo GS (2009) Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4(3):206\u2013216","journal-title":"Cell Stem Cell"},{"issue":"10","key":"4096_CR156","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/stem.3242","volume":"38","author":"JL Liesveld","year":"2020","unstructured":"Liesveld JL, Sharma N, Aljitawi OS (2020) Stem cell homing: from physiology to therapeutics. Stem Cells 38(10):1241\u20131253","journal-title":"Stem Cells"},{"issue":"6","key":"4096_CR157","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/stem.2614","volume":"35","author":"F Nitzsche","year":"2017","unstructured":"Nitzsche F, Muller C, Lukomska B, Jolkkonen J, Deten A, Boltze J (2017) Concise review: MSC adhesion cascade-insights into homing and transendothelial migration. Stem Cells 35(6):1446\u20131460","journal-title":"Stem Cells"},{"key":"4096_CR158","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.isci.2019.05.004","volume":"15","author":"M Ullah","year":"2019","unstructured":"Ullah M, Liu DD, Thakor AS (2019) Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience 15:421\u2013438","journal-title":"iScience"},{"issue":"14","key":"4096_CR159","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.3390\/ijms20143529","volume":"20","author":"KH Lee","year":"2019","unstructured":"Lee KH, Tseng WC, Yang CY, Tarng DC (2019) The anti-inflammatory, anti-oxidative, and anti-apoptotic benefits of stem cells in acute ischemic kidney injury. Int J Mol Sci 20(14):3529","journal-title":"Int J Mol Sci"},{"issue":"5","key":"4096_CR160","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 17(5):533\u2013535","journal-title":"Cell Mol Immunol"},{"key":"4096_CR161","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1038\/emm.2013.94","volume":"45","author":"MB Murphy","year":"2013","unstructured":"Murphy MB, Moncivais K, Caplan AI (2013) Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 45:e54","journal-title":"Exp Mol Med"},{"issue":"3","key":"4096_CR162","doi-asserted-by":"publisher","first-page":"L360","DOI":"10.1152\/ajplung.00153.2017","volume":"314","author":"O Bernard","year":"2018","unstructured":"Bernard O, Jeny F, Uzunhan Y, Dondi E, Terfous R, Label R, Sutton A, Larghero J, Vanneaux V, Nunes H et al (2018) Mesenchymal stem cells reduce hypoxia-induced apoptosis in alveolar epithelial cells by modulating HIF and ROS hypoxic signaling. Am J Physiol Lung Cell Mol Physiol 314(3):L360\u2013L371","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"1","key":"4096_CR163","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13287-018-0774-8","volume":"9","author":"M Khatri","year":"2018","unstructured":"Khatri M, Richardson LA, Meulia T (2018) Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model. Stem Cell Res Ther 9(1):17","journal-title":"Stem Cell Res Ther"},{"issue":"7","key":"4096_CR164","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1089\/vim.2016.0140","volume":"30","author":"F Li","year":"2017","unstructured":"Li F, Karlsson H (2017) Antiviral effect of IDO in mouse fibroblast cells during influenza virus infection. Viral Immunol 30(7):542\u2013544","journal-title":"Viral Immunol"},{"issue":"Pt 1","key":"4096_CR165","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1099\/vir.0.045013-0","volume":"94","author":"S Tripathi","year":"2013","unstructured":"Tripathi S, Tecle T, Verma A, Crouch E, White M, Hartshorn KL (2013) The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J Gen Virol 94(Pt 1):40\u201349","journal-title":"J Gen Virol"},{"key":"4096_CR166","doi-asserted-by":"publisher","first-page":"100019","DOI":"10.1016\/j.medidd.2020.100019","volume":"5","author":"SM Metcalfe","year":"2020","unstructured":"Metcalfe SM (2020) Mesenchymal stem cells and management of COVID-19 pneumonia. Med Drug Discov 5:100019","journal-title":"Med Drug Discov"},{"issue":"4","key":"4096_CR167","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/stem.3140","volume":"38","author":"YH Hur","year":"2020","unstructured":"Hur YH, Cerione RA, Antonyak MA (2020) Extracellular vesicles and their roles in stem cell biology. Stem Cells 38(4):469\u2013476","journal-title":"Stem Cells"},{"issue":"4","key":"4096_CR168","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel G, D\u2019Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19(4):213\u2013228","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"4096_CR169","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41580-020-0251-y","volume":"21","author":"K O'Brien","year":"2020","unstructured":"O\u2019Brien K, Breyne K, Ughetto S, Laurent LC, Breakefield XO (2020) RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat Rev Mol Cell Biol 21(10):585\u2013606","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4096_CR170","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fncel.2016.00109","volume":"10","author":"S Koniusz","year":"2016","unstructured":"Koniusz S, Andrzejewska A, Muraca M, Srivastava AK, Janowski M, Lukomska B (2016) Extracellular vesicles in physiology, pathology, and therapy of the immune and central nervous system, with focus on extracellular vesicles derived from mesenchymal stem cells as therapeutic tools. Front Cell Neurosci 10:109","journal-title":"Front Cell Neurosci"},{"issue":"1","key":"4096_CR171","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/sctm.19-0205","volume":"9","author":"A Abraham","year":"2020","unstructured":"Abraham A, Krasnodembskaya A (2020) Mesenchymal stem cell-derived extracellular vesicles for the treatment of acute respiratory distress syndrome. Stem Cells Transl Med 9(1):28\u201338","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"4096_CR172","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1007\/s12015-020-10085-8","volume":"17","author":"H Guo","year":"2021","unstructured":"Guo H, Su Y, Deng F (2021) Effects of mesenchymal stromal cell-derived extracellular vesicles in lung diseases: current status and future perspectives. Stem Cell Rev Rep 17(2):440\u2013458","journal-title":"Stem Cell Rev Rep"},{"key":"4096_CR173","doi-asserted-by":"publisher","first-page":"108712","DOI":"10.1016\/j.clim.2021.108712","volume":"226","author":"M Dauletova","year":"2021","unstructured":"Dauletova M, Hafsan H, Mahhengam N, Zekiy AO, Ahmadi M, Siahmansouri H (2021) Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: a review study. Clin Immunol 226:108712","journal-title":"Clin Immunol"},{"issue":"10","key":"4096_CR174","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1164\/rccm.201701-0170OC","volume":"196","author":"TJ Morrison","year":"2017","unstructured":"Morrison TJ, Jackson MV, Cunningham EK, Kissenpfennig A, McAuley DF, O\u2019Kane CM, Krasnodembskaya AD (2017) Mesenchymal stromal cells modulate macrophages in clinically relevant lung injury models by extracellular vesicle mitochondrial transfer. Am J Respir Crit Care Med 196(10):1275\u20131286","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"4096_CR175","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1164\/rccm.201410-1765OC","volume":"192","author":"A Monsel","year":"2015","unstructured":"Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, Rosenzwajg M, Matthay MA, Lee JW (2015) Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med 192(3):324\u2013336","journal-title":"Am J Respir Crit Care Med"},{"key":"4096_CR176","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejphar.2019.01.022","volume":"852","author":"JW Li","year":"2019","unstructured":"Li JW, Wei L, Han Z, Chen Z (2019) Mesenchymal stromal cells-derived exosomes alleviate ischemia\/reperfusion injury in mouse lung by transporting anti-apoptotic miR-21-5p. Eur J Pharmacol 852:68\u201376","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4096_CR177","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s12015-020-10110-w","volume":"17","author":"A Basiri","year":"2021","unstructured":"Basiri A, Mansouri F, Azari A, Ranjbarvan P, Zarein F, Heidari A, Golchin A (2021) Stem cell therapy potency in personalizing severe COVID-19 treatment. Stem Cell Rev Rep 17(1):193\u2013213","journal-title":"Stem Cell Rev Rep"},{"key":"4096_CR178","doi-asserted-by":"publisher","first-page":"102239","DOI":"10.1016\/j.scr.2021.102239","volume":"52","author":"C Musial","year":"2021","unstructured":"Musial C, Gorska-Ponikowska M (2021) Medical progress: stem cells as a new therapeutic strategy for COVID-19. Stem Cell Res 52:102239","journal-title":"Stem Cell Res"},{"issue":"1","key":"4096_CR179","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/labmed\/lmaa049","volume":"52","author":"KK Sahu","year":"2021","unstructured":"Sahu KK, Siddiqui AD, Cerny J (2021) Mesenchymal stem cells in COVID-19: a journey from bench to bedside. Lab Med 52(1):24\u201335","journal-title":"Lab Med"},{"issue":"2","key":"4096_CR180","doi-asserted-by":"publisher","first-page":"216","DOI":"10.14336\/AD.2020.0228","volume":"11","author":"Z Leng","year":"2020","unstructured":"Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S et al (2020) Transplantation of ACE2(\u2212) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 11(2):216\u2013228","journal-title":"Aging Dis"},{"issue":"2","key":"4096_CR181","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1002\/ctm2.297","volume":"11","author":"X Xu","year":"2021","unstructured":"Xu X, Jiang W, Chen L, Xu Z, Zhang Q, Zhu M, Ye P, Li H, Yu L, Zhou X et al (2021) Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: an exploratory clinical trial. Clin Transl Med 11(2):e297","journal-title":"Clin Transl Med"},{"issue":"1","key":"4096_CR182","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-020-00286-5","volume":"5","author":"F Meng","year":"2020","unstructured":"Meng F, Xu R, Wang S, Xu Z, Zhang C, Li Y, Yang T, Shi L, Fu J, Jiang T et al (2020) Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther 5(1):172","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4096_CR183","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-021-00488-5","volume":"6","author":"L Shi","year":"2021","unstructured":"Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, Wang S, Zhang C, Yuan X, Xu Z et al (2021) Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther 6(1):58","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"4096_CR184","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/sctm.20-0472","volume":"10","author":"G Lanzoni","year":"2021","unstructured":"Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, Alvarez Gil A, Poggioli R, Ruiz P, Marttos AC et al (2021) Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1\/2a, randomized controlled trial. Stem Cells Transl Med 10(5):660\u2013673","journal-title":"Stem Cells Transl Med"},{"issue":"1","key":"4096_CR185","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1186\/s13287-020-01875-5","volume":"11","author":"L Shu","year":"2020","unstructured":"Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, Ji N, Zheng Y, Chen X, Shi L et al (2020) Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther 11(1):361","journal-title":"Stem Cell Res Ther"},{"key":"4096_CR186","doi-asserted-by":"publisher","first-page":"100454","DOI":"10.1016\/j.eclinm.2020.100454","volume":"25","author":"F S\u00e1nchez-Guijo","year":"2020","unstructured":"S\u00e1nchez-Guijo F, Garc\u00eda-Arranz M, L\u00f3pez-Parra M, Monedero P, Mata-Mart\u00ednez C, Santos A, Sagredo V, \u00c1lvarez-Avello J-M, Guerrero JE, P\u00e9rez-Calvo C et al (2020) Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation. A proof of concept study. EClinicalMedicine 25:100454","journal-title":"EClinicalMedicine"},{"issue":"12","key":"4096_CR187","doi-asserted-by":"publisher","first-page":"e12947","DOI":"10.1111\/cpr.12947","volume":"53","author":"Y Feng","year":"2020","unstructured":"Feng Y, Huang J, Wu J, Xu Y, Chen B, Jiang L, Xiang H, Peng Z, Wang X (2020) Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: a pilot study. Cell Prolif 53(12):e12947","journal-title":"Cell Prolif"},{"issue":"1","key":"4096_CR188","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13287-021-02165-4","volume":"12","author":"SR Hashemian","year":"2021","unstructured":"Hashemian SR, Aliannejad R, Zarrabi M, Soleimani M, Vosough M, Hosseini SE, Hossieni H, Keshel SH, Naderpour Z, Hajizadeh-Saffar E et al (2021) Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series. Stem Cell Res Ther 12(1):91","journal-title":"Stem Cell Res Ther"},{"key":"4096_CR189","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21037\/sci-2020-024","volume":"7","author":"R Zengin","year":"2020","unstructured":"Zengin R, Beyaz O, Koc ES, Akinci IO, Kocagoz S, Sagcan G, Ovali E, Cuhadaroglu C (2020) Mesenchymal stem cell treatment in a critically ill COVID-19 patient: a case report. Stem Cell Investig 7:17","journal-title":"Stem Cell Investig"},{"issue":"31","key":"4096_CR190","doi-asserted-by":"publisher","first-page":"e21429","DOI":"10.1097\/MD.0000000000021429","volume":"99","author":"B Liang","year":"2020","unstructured":"Liang B, Chen J, Li T, Wu H, Yang W, Li Y, Li J, Yu C, Nie F, Ma Z et al (2020) Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: a case report. Medicine (Baltimore) 99(31):e21429","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"4096_CR191","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s13287-020-01725-4","volume":"11","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Ding J, Ren S, Wang W, Yang Y, Li S, Meng M, Wu T, Liu D, Tian S et al (2020) Intravenous infusion of human umbilical cord Wharton\u2019s jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia. Stem Cell Res Ther 11(1):207","journal-title":"Stem Cell Res Ther"},{"issue":"5","key":"4096_CR192","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s11684-020-0810-9","volume":"14","author":"L Tang","year":"2020","unstructured":"Tang L, Jiang Y, Zhu M, Chen L, Zhou X, Zhou C, Ye P, Chen X, Wang B, Xu Z et al (2020) Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID-19. Front Med 14(5):664\u2013673","journal-title":"Front Med"},{"issue":"30","key":"4096_CR193","doi-asserted-by":"publisher","first-page":"eaba6884","DOI":"10.1126\/sciadv.aba6884","volume":"6","author":"O Levy","year":"2020","unstructured":"Levy O, Kuai R, Siren EMJ, Bhere D, Milton Y, Nissar N, De Biasio M, Heinelt M, Reeve B, Abdi R et al (2020) Shattering barriers toward clinically meaningful MSC therapies. Sci Adv 6(30):eaba6884","journal-title":"Sci Adv"},{"issue":"23","key":"4096_CR194","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020006000","volume":"135","author":"JM Connors","year":"2020","unstructured":"Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticoagulation. Blood 135(23):2033\u20132040","journal-title":"Blood"},{"issue":"5","key":"4096_CR195","doi-asserted-by":"publisher","first-page":"e2010478","DOI":"10.1001\/jamanetworkopen.2020.10478","volume":"3","author":"J Nahum","year":"2020","unstructured":"Nahum J, Morichau-Beauchant T, Daviaud F, Echegut P, Fichet J, Maillet JM, Thierry S (2020) Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19). JAMA Netw Open 3(5):e2010478","journal-title":"JAMA Netw Open"},{"issue":"5","key":"4096_CR196","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/s41577-021-00536-9","volume":"21","author":"A Bonaventura","year":"2021","unstructured":"Bonaventura A, Vecchie A, Dagna L, Martinod K, Dixon DL, Van Tassell BW, Dentali F, Montecucco F, Massberg S, Levi M et al (2021) Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat Rev Immunol 21(5):319\u2013329","journal-title":"Nat Rev Immunol"},{"key":"4096_CR197","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1136\/thoraxjnl-2020-216243","volume":"76","author":"J Loo","year":"2021","unstructured":"Loo J, Spittle DA, Newnham M (2021) COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax 76:412\u2013420","journal-title":"Thorax"},{"issue":"24","key":"4096_CR198","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1001\/jama.2020.23422","volume":"324","author":"G Piazza","year":"2020","unstructured":"Piazza G, Morrow DA (2020) Diagnosis, management, and pathophysiology of arterial and venous thrombosis in COVID-19. JAMA 324(24):2548\u20132549","journal-title":"JAMA"},{"issue":"2","key":"4096_CR199","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.molmed.2018.12.006","volume":"25","author":"G Moll","year":"2019","unstructured":"Moll G, Ankrum JA, Kamhieh-Milz J, Bieback K, Ringden O, Volk HD, Geissler S, Reinke P (2019) Intravascular mesenchymal stromal\/stem cell therapy product diversification: time for new clinical guidelines. Trends Mol Med 25(2):149\u2013163","journal-title":"Trends Mol Med"},{"key":"4096_CR200","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-3-319-45457-3_7","volume":"951","author":"G Moll","year":"2016","unstructured":"Moll G, Geissler S, Catar R, Ignatowicz L, Hoogduijn MJ, Strunk D, Bieback K, Ringden O (2016) Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy? Adv Exp Med Biol 951:77\u201398","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"4096_CR201","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1002\/stem.1729","volume":"32","author":"G Moll","year":"2014","unstructured":"Moll G, Alm JJ, Davies LC, von Bahr L, Heldring N, Stenbeck-Funke L, Hamad OA, Hinsch R, Ignatowicz L, Locke M et al (2014) Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells 32(9):2430\u20132442","journal-title":"Stem Cells"},{"issue":"5","key":"4096_CR202","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.chest.2016.10.061","volume":"151","author":"MK Glassberg","year":"2017","unstructured":"Glassberg MK, Minkiewicz J, Toonkel RL, Simonet ES, Rubio GA, DiFede D, Shafazand S, Khan A, Pujol MV, LaRussa VF et al (2017) Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial. Chest 151(5):971\u2013981","journal-title":"Chest"},{"issue":"7","key":"4096_CR203","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/resp.12343","volume":"19","author":"DC Chambers","year":"2014","unstructured":"Chambers DC, Enever D, Ilic N, Sparks L, Whitelaw K, Ayres J, Yerkovich ST, Khalil D, Atkinson KM, Hopkins PM (2014) A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology 19(7):1013\u20131018","journal-title":"Respirology"},{"key":"4096_CR204","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1465-9921-15-39","volume":"15","author":"G Zheng","year":"2014","unstructured":"Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, Deng K, Zhang L, Zou B, Cheng B et al (2014) Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 15:39","journal-title":"Respir Res"},{"key":"4096_CR205","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1002\/cbin.11440","volume":"44","author":"MS Choudhery","year":"2020","unstructured":"Choudhery MS, Harris DT (2020) Stem cell therapy for COVID-19: possibilities and challenges. Cell Biol Int 44:2182\u20132191","journal-title":"Cell Biol Int"},{"issue":"1","key":"4096_CR206","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12015-020-10046-1","volume":"17","author":"A Golchin","year":"2021","unstructured":"Golchin A (2021) Cell-based therapy for severe COVID-19 patients: clinical trials and cost-utility. Stem Cell Rev Rep 17(1):56\u201362","journal-title":"Stem Cell Rev Rep"},{"issue":"4","key":"4096_CR207","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8(4):315\u2013317","journal-title":"Cytotherapy"},{"issue":"1","key":"4096_CR208","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s13287-020-01802-8","volume":"11","author":"H Peng","year":"2020","unstructured":"Peng H, Gong T, Huang X, Sun X, Luo H, Wang W, Luo J, Luo B, Chen Y, Wang X et al (2020) A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report. Stem Cell Res Ther 11(1):291","journal-title":"Stem Cell Res Ther"},{"issue":"2","key":"4096_CR209","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00018-020-03600-0","volume":"78","author":"LA Costa","year":"2021","unstructured":"Costa LA, Eiro N, Fraile M, Gonzalez LO, Saa J, Garcia-Portabella P, Vega B, Schneider J, Vizoso FJ (2021) Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses. Cell Mol Life Sci 78(2):447\u2013467","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"4096_CR210","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s13287-021-02265-1","volume":"12","author":"A Markov","year":"2021","unstructured":"Markov A, Thangavelu L, Aravindhan S, Zekiy AO, Jarahian M, Chartrand MS, Pathak Y, Marofi F, Shamlou S, Hassanzadeh A (2021) Mesenchymal stem\/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem Cell Res Ther 12(1):192","journal-title":"Stem Cell Res Ther"},{"issue":"4","key":"4096_CR211","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2174\/1574888X16999201124224816","volume":"16","author":"AC Tufan","year":"2021","unstructured":"Tufan AC (2021) Mesenchymal stem cells as a treatment strategy for coronavirus disease 2019 (COVID-19): need for authority regulations and clinical guidelines. Curr Stem Cell Res Ther 16(4):465\u2013480","journal-title":"Curr Stem Cell Res Ther"},{"issue":"Suppl 2","key":"4096_CR212","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1002\/sctm.21-0083","volume":"10","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Han Z, Wang J, Han Z (2021) Development and investigational new drug application of mesenchymal stem\/stromal cells products in China. Stem Cells Transl Med 10(Suppl 2):S18\u2013S30","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"4096_CR213","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/ID9.0000000000000016","volume":"1","author":"R Xu","year":"2021","unstructured":"Xu R, Shi L, Xie W-F, Xu Z, Meng F-P, Fu J-L, Yuan X, Huang L, Shi M, Li Y et al (2021) Diagnosis and treatment guidelines for mesenchymal stem cell therapy for coronavirus disease 2019 (Beijing, 2021). Infect Dis Immun 1(2):68\u201373","journal-title":"Infect Dis Immun"},{"key":"4096_CR214","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ijid.2020.05.040","volume":"96","author":"A Zumla","year":"2020","unstructured":"Zumla A, Wang FS, Ippolito G, Petrosillo N, Agrati C, Azhar EI, Chang C, El-Kafrawy SA, Osman M, Zitvogel L et al (2020) Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of mesenchymal stromal (stem) cell (MSC) therapy\u2014achieving global consensus and visibility for cellular host-directed therapies. Int J Infect Dis 96:431\u2013439","journal-title":"Int J Infect Dis"},{"issue":"1","key":"4096_CR215","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1080\/01652176.2020.1766725","volume":"40","author":"R Tiwari","year":"2020","unstructured":"Tiwari R, Dhama K, Sharun K, Iqbal Yatoo M, Malik YS, Singh R, Michalak I, Sah R, Bonilla-Aldana DK, Rodriguez-Morales AJ (2020) COVID-19: animals, veterinary and zoonotic links. Vet Q 40(1):169\u2013182","journal-title":"Vet Q"},{"issue":"1","key":"4096_CR216","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s12015-020-10002-z","volume":"17","author":"L Pinky","year":"2021","unstructured":"Pinky L, Gupta S, Krishnakumar V, Sharma Y, Dinda AK, Mohanty S (2021) Mesenchymal stem cell derived exosomes: a nano platform for therapeutics and drug delivery in combating COVID-19. Stem Cell Rev Rep 17(1):33\u201343","journal-title":"Stem Cell Rev Rep"},{"key":"4096_CR217","doi-asserted-by":"publisher","first-page":"105009","DOI":"10.1016\/j.chemphyslip.2020.105009","volume":"234","author":"L Rezakhani","year":"2021","unstructured":"Rezakhani L, Kelishadrokhi AF, Soleimanizadeh A, Rahmati S (2021) Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: real opportunities and range of promises. Chem Phys Lipids 234:105009","journal-title":"Chem Phys Lipids"},{"issue":"12","key":"4096_CR218","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1089\/scd.2020.0080","volume":"29","author":"V Sengupta","year":"2020","unstructured":"Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N (2020) Exosomes derived from bone marrow mesenchymal stem cells as treatment for severe COVID-19. Stem Cells Dev 29(12):747\u2013754","journal-title":"Stem Cells Dev"},{"key":"4096_CR219","doi-asserted-by":"publisher","first-page":"587866","DOI":"10.3389\/fcell.2020.587866","volume":"8","author":"DH Kassem","year":"2020","unstructured":"Kassem DH, Kamal MM (2020) Mesenchymal stem cells and their extracellular vesicles: a potential game changer for the COVID-19 crisis. Front Cell Dev Biol 8:587866","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"4096_CR220","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1186\/s13287-020-01866-6","volume":"11","author":"A Akbari","year":"2020","unstructured":"Akbari A, Rezaie J (2020) Potential therapeutic application of mesenchymal stem cell-derived exosomes in SARS-CoV-2 pneumonia. Stem Cell Res Ther 11(1):356","journal-title":"Stem Cell Res Ther"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-04096-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-021-04096-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-04096-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T20:22:12Z","timestamp":1700252532000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-021-04096-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,20]]},"references-count":220,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["4096"],"URL":"https:\/\/doi.org\/10.1007\/s00018-021-04096-y","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,20]]},"assertion":[{"value":"20 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"142"}}